Pancreatic Cell Reprogramming With Small-Molecule TGFβ Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming cells derived from mammalian pancreatic tissue into pancreatic stem/progenitor cells involve genetic modification, posing risks and limitations for clinical application in regenerative medicine.
Innovation Solution
A method involving the use of TGFβ-receptor, GSK3, and ROCK inhibitors to reprogram mature pancreatic cells into pancreatic stem/progenitor cells without genetic modification, using low molecular weight compounds such as A-83-01, CHIR99021, and Y-27632 in a controlled culture environment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic modification methods (iPS cells or direct reprogramming) are used to reprogram cells, then reprogramming capability is achieved, but tumorigenesis risk and safety issues arise
Solution Approach 1:
The invention extracts and eliminates the harmful genetic modification step from the reprogramming process. Instead of using viral vectors or genetic transduction to induce pluripotency, the method employs small molecule inhibitors (TGFβ-receptor inhibitor, GSK3 inhibitor, and ROCK inhibitor) that temporarily modulate signaling pathways to enable reprogramming without integrating foreign genetic material, thereby removing the source of tumorigenesis risk
Solution Approach 2:
The invention changes the chemical parameters of the reprogramming process by using low molecular weight compound inhibitors instead of genetic materials. The specific parameters include using TGFβ-receptor inhibitor (e.g., A-83-01), GSK3 inhibitor (e.g., CHIR99021), and ROCK inhibitor (e.g., Y-27632) at controlled concentrations to modulate cellular signaling pathways, achieving reprogramming through biochemical parameter modulation rather than genetic alteration
2Reliability
If no reprogramming method is used, then genetic modification risks are avoided, but the ability to produce stem/progenitor cells for regenerative medicine is lost
Solution Approach 1:
The invention introduces small molecule inhibitors as intermediary substances that mediate the reprogramming process. These inhibitors (TGFβ-receptor inhibitor, GSK3 inhibitor, ROCK inhibitor) act as temporary mediators that modulate signaling pathways to enable mature cells to transition to stem/progenitor cell states without permanent genetic modification, thus achieving both safety and productivity
Solution Approach 2:
The invention performs preliminary actions by treating mature cells with a combination of inhibitors before the actual reprogramming occurs. The TGFβ-receptor inhibitor, GSK3 inhibitor, and ROCK inhibitor are applied in sequence or combination to prepare the cellular environment, suppress differentiation signals, and activate stemness pathways in advance, enabling efficient reprogramming without genetic modification
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method starting from cells derived from a mammalian endodermal tissue or organ (except for the liver) to produce stem/progenitor cells thereof, which comprises bringing the cells derived from the endodermal tissue or organ into contact in vitro with a TGFβ-receptor inhibitor.